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	The microtubule associated protein tau is implicated in a broad range of neurodegenerative 
diseases collectively known as tauopathies, characterized by the accumulation of 
hyperphosphorylated and ubiquitinated insoluble aggregates of tau. To date, numerous studies 
have aimed to identify cellular pathways regulating the aggregation of tau. However, while 
several genetic screens utilizing Drosophila models of tau have been performed, no genome-
wide screens using mammalian cells for modulators of tau aggregation have been reported. 
This is caused in part because no simple cell culture models of tau aggregation were available, 
since tau is a highly soluble, natively disordered protein, and overexpression alone does not 
induce aggregation of tau, as is the case for the poly-glutamine repeat expansion proteins. 
Recently, Sanders et al. reported a tau aggregation model cell line based on the microtubule 
binding repeat domain of tau (tau RD) that indefinitely propagates aggregates even after cell 
division (Neuron, 2014). Therefore, we performed a genome-wide siRNA screen for 
modulators of tau RD aggregation through utilizing this cell culture model. 
 We first independently reproduced the tau RD aggregation-propagating model cell line.  
HEK293A cells stably expressing tau RD fused to Venus was established (Fig. 1A). To 
increase the aggregation of tau RD, we introduced the P301L mutation, which is a causative 
mutation of frontotemporal dementia and is known to increase the aggregation propensity of 
tau. We next generated recombinant tau RD fibrils in vitro through incubation of purified tau 
RD with heparin (Fig. 1B). These recombinant tau RD fibrils were transduced into HEK293A 
cells stably expressing tau RD P301L-Venus through lipofection to induce aggregation of tau 
RD. Fibril-transduced cells containing tau RD aggregates were sparsely diluted, and 
monoclonal cell lines stably propagating tau RD aggregates, hereafter referred to as 
aggregate-positive cells, were obtained (Fig. 1C). 
 We used these aggregate-positive cells to perform high-content genome-wide siRNA 
screening based on quantification of the total intensity of cytoplasmic tau RD aggregates (Fig. 
2A). For the 1st screening, we used a genome-wide siRNA library targeting approximately 
18,000 genes, with 4 pooled siRNA constructs per gene, and selected 283 genes as 
significantly enhancing tau RD aggregation when knocked down (Fig. 2B). Representative 
images from the 1st screening are shown in Fig. 2C. To reduce off-target effects, from the 2nd 
screening, we used two different cell types and chemically modified siRNAs (Fig 2D). For 
the 2nd screening, we validated results of the 1st screening using HEK293A and U2OS tau RD 
aggregate-positive cell lines, again with 4 pooled siRNA constructs. Genes that were positive 
in both cell lines were taken as hits. Among these hit genes, we reasoned that some genes 
	would affect general protein degradation. To eliminate such genes, we performed a counter 
screen using HEK293A and U2OS cells stably expressing ZsGreen-mODC, a well-
characterized proteasome model substrate consisting of the fluorescent protein ZsGreen fused 
to a mouse ornithine decarboxylase degron. Genes that caused accumulation of ZsGreen-
mODC when knocked down likely affected proteasome activity, and were therefore removed 
from 2nd screening hits, resulting in 35 aggregation suppressor candidate genes. Finally, to 
further remove off-target effects, each of the 4 pooled siRNAs were tested individually in 
both HEK293A and U2OS tau RD aggregate-positive cell lines for the 3rd screening. Genes 
for which more than 3 of 4 individual siRNAs tested enhanced tau aggregation in either 
HEK293A or U2OS cells were chosen, resulting in 14 candidate aggregation suppressor 
genes. 
 Among these 14 genes, three genes were positive for 4 of 4 siRNA constructs tested in 
both cell lines (Fig. 2E). Of these, two were components of the SUMO modification 
(SUMOylation) pathway: SUMO2, and SAE1, a subunit of the SUMO activating E1 enzyme 
heterodimer. We therefore decided to investigate the role of SUMOylation on the aggregation 
of tau RD. Human cells express three isoforms of SUMO, of which SUMO2 and SUMO3 are 
nearly identical and often regarded as one protein, SUMO2/3, while SUMO1 is only about 
50% identical to SUMO2/3. Therefore, we first tested the specificity of SUMO1 and 
SUMO2/3 modification through using 4 siRNA constructs against SUMO1, SUMO2, and 
SUMO3. We confirmed that only SUMO2 knockdown caused accumulation of tau RD 
aggregates in both HEK293A and U2OS cells. We further validated SUMO1 versus 
SUMO2/3 knockdown specificity on tau RD aggregation by flow cytometry following 
digitonin treatment to remove soluble tau RD, and confirmed that while knockdown of 
SUMO2/3 resulted in about a three-fold increase compared to non-targeting control siRNA, 
knockdown of SUMO1 had almost no effect on tau RD aggregates (Fig. 3A). 
 To facilitate immunoprecipitation (IP) of tau RD, we next established a HEK293T cell 
line stably expressing tau RD P301L-Flag-Halo (Fig. 1A). Using an aggregate-positive form 
of this cell line, SUMO1 and SUMO2/3 were knocked down, and the ubiquitination of tau 
RD-Flag-Halo was analyzed by Flag-IP followed by blotting for tau RD and K48-linked 
ubiquitin (Fig. 3B). This revealed that knockdown of SUMO1 and SUMO2/3 both increased 
the ubiquitination levels of soluble tau RD, with SUMO2/3 having a larger effect. In contrast, 
both SUMO1 and SUMO2/3 knockdown did not significantly affect the ubiquitination of 
insoluble tau RD. 
	 We next investigated if tau RD was directly SUMOylated by overexpressing Myc-
tagged SUMO1 or SUMO2 in a HEK293T tau RD aggregate-positive cell line, followed by 
Flag-IP of tau RD. Immunoblot analysis of immunoprecipitated tau RD from total cell lysate 
revealed additional higher molecular weight bands above that expected for tau RD (Fig. 4A). 
Comparison with immunoblots to detect SUMO and K48-linked ubiquitin revealed these 
bands to be due to both ubiquitination and SUMOylation of tau RD. Consistent with the effect 
of SUMO1 and SUMO2/3 knockdown increasing the ubiquitination of tau RD, we found that 
when UBE2I was overexpressed, there was a decrease in ubiquitination of tau RD. We then 
performed the same experiment using a HEK293T tau RD aggregate-negative cell line, and 
found that tau RD was also SUMOylated, and to a higher extent than in the aggregate-positive 
cell line (Fig. 4B). 
 Next, since the majority of tau RD expressed in aggregate-negative cell lines are 
soluble, we reasoned that SUMOylation may target soluble tau RD. We tested this through IP 
of tau RD from both the 0.2% Triton X-100 soluble and insoluble fractions of a tau RD 
aggregate-positive cell line. We found that soluble tau RD was mostly SUMOylated, while 
insoluble tau RD was mainly ubiquitinated (Fig. 5A and 5B). 
 Taken together, our results suggest a mechanism where SUMOylation competes with 
ubiquitination to prevent the aggregation of tau RD. While we do not currently have sufficient 
data to present a more detailed model, past studies have shown that SUMOylation can 
increase the solubility and inhibit the aggregation of misfolded proteins. Furthermore, 
SUMOylation has been shown to compete with the same lysine residue with ubiquitination, 
for example for IκB-α. Therefore, we propose a working hypothesis in which SUMO2 
modification of tau RD maintains tau RD in a soluble state, thus inhibiting its aggregation and 
ubiquitination (5 年以内に出版予定). 
  
	 
  
Figure 1. Establishment of tau RD aggregate positive cell lines. A. Schematic of constructs used in this study. The 
microtubule binding repeat domain (RD) from the 2N4R isoform of full-length tau was fused with an N-terminal GST-tag 
for recombinant tau RD production, and a C-terminal Venus or Flag-Halo-tag for cell culture experiments. To increase 
aggregation propensity, the P301L FTLD-17 mutation was introduced for all cell culture experiments. B. 
Ultracentrifugation analysis of recombinant tau RD fibrils obtained through incubation with heparin. After incubation 
with heparin, samples were centrifuged at 100,000 x g for 1 h, and divided into Total (before ultracentrifugation), 
soluble (Sup) and insoluble (Pel) fractions. The insoluble fraction was further sonicated (soni) to generate tau RD fibril 
seeds for transduction into cell cultures. C. Scheme for the establishment of cell lines stably propagating tau RD 
aggregates. A cell line stably expressing tau RD P301L-Venus was seeded with recombinant tau RD fibrils via 
lipofection. These seeded cells were then isolated and cloned into monoclonal cell lines stably propagating tau RD 
aggregates. 
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Figure 2. Genome-wide siRNA screening identifies 14 aggregation enhancing siRNAs. A. Schematic of high 
content image analysis. A region of set width (ring) around DAPI-stained nuclei (circle) was defined, and GFP spots 
within the ring were detected to quantify cytoplasmic tau RD aggregates. B. B scores of all samples in the 1st genome-
wide siRNA screen based on cytoplasmic aggregate total fluorescence intensity. The cutoff value for siRNAs 
enhancing tau RD aggregation is indicated as a dashed red line. C. Representative images from the 1st screen. The 
cutoff value was decided based on inspection of such images as the value at which a clear difference between siRNAs 
with no effect (B score close to 0) and potential hit genes were visible. D. Overview of the siRNA screening protocol. 14 
final candidate genes were obtained from approximately 18,000 siRNAs. E. Table of the 14 final candidate genes and 
an overview of their scores during the screening process.
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Figure 3. Knockdown of SUMO2/3, but not SUMO1, affects tau aggregation and ubiquitination. A. HEK293A tau 
RD P301L-Venus clone No. 2-2+ cells were treated with the indicated siRNAs for 96 h, photographed, and then 
analyzed by flow cytometry through measuring Venus fluorescence intensity with and without digitonin treatment. 
Values are expressed as relative values with control siRNA (siCtrl) treatment set to 1. B. Effect of SUMO knockdown 
on the ubiquitination of tau RD. HEK293T tau RD P301L-Flag-Halo cells with tau RD aggregates (clone No. 2+) was 
treated with the indicated siRNAs, and tau RD was immunoprecipitated by Flag-IP from 0.2 % Triton X-100 soluble and 
insoluble fractions, and analyzed by immunoblot with the indicated antibodies.  
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Figure 4. Tau RD is directly SUMOylated in both aggregate-positive and aggregate-negative cells A. Detection 
of tau RD SUMOylation by SUMO overexpression and immunoprecipitation of tau RD. HEK293T tau RD P301L-Flag-
Halo cells with tau RD aggregates (clone No. 3+) was transfected with the SUMO E2 ligase UBE2I and Myc-tagged 
SUMO1, SUMO2, or SUMO2Q90P (resistant to cleavage by SENP SUMO peptidases) as indicated, then tau RD was 
immunoprecipitated by Flag-IP from the 0.1% SDS soluble fraction. Bands due to SUMOylated and ubiquitinated tau 
RD are indicated as open and filled circles, respectively, based on comparison of the anti-Halo (tau RD) blots with the 
anti-Myc (SUMO) and anti-K48 ubiquitin blots. B. As in A, except that HEK293T tau RD P301L-Flag-Halo cells without 
tau RD aggregates (clone No. 2-) was used instead.
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IP from 0.2% Triton X-100 insoluble fraction 
Figure 5. Soluble tau RD is SUMOylated, while insoluble tau RD is ubiquitinated A. Detection of tau RD 
SUMOylation by SUMO overexpression and immunoprecipitation of tau RD. HEK293T tau RD P301L-Flag-Halo cells 
with tau RD aggregates (clone No. 3+) was transfected as indicated, and tau RD was immunoprecipitated from the 0.2 
% Triton X-100 soluble fraction. Bands due to SUMOylated and ubiquitinated tau RD are indicated as open and filled 
circles, respectively, based on comparison of the anti-Halo (tau RD) blots with the anti-Myc (SUMO) and anti-K48 
ubiquitin blots. B. As in A, but Flag-IP from the 0.2 % Triton X-100 insoluble fraction.
